Generated by Meeveem AI
"The global leader in generics and biosimilars, pioneering access for patients"
Sandoz develops and manufactures generic and biosimilar medicines, providing more affordable versions of high-quality treatments once key patents expire. With approximately 1,300 medicines including over 50 critical antibiotics and 13 biosimilars, the company treats life-threatening diseases such as cancer, diabetes, and arthritis. Operating globally since 1886, Sandoz delivered more than 900 million patient treatments in 2024. The company addresses rising healthcare costs by enabling broader access to proven medicines. Patients, healthcare systems, and caregivers benefit from reduced treatment expenses without compromising quality. In 2024, Sandoz generated over USD 19 billion in direct savings for US and European healthcare systems.
23000
Team Members
1886
Founded
Pharma
Sector
Hybrid
Work Environment
A world where patients can access the medicines they need at the right time, regardless of cost, making proven treatments universally available and healthcare systems sustainable for future generations.
At Sandoz, our mission is to pioneer access for patients by developing more affordable versions of high-quality medicines once their key patents have expired.